title: Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient.
authors.affiliation: Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Switzerland. bodmerm@uhbs.ch
authors.forename: Michael
authors.initials: M
authors.lastname: Bodmer
authors.forename: Patrizia
authors.initials: P
authors.lastname: Amico
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Mihatsch
authors.forename: Manuel
authors.initials: M
authors.lastname: Haschke
authors.forename: Oliver
authors.initials: O
authors.lastname: Kummer
authors.forename: Stephan
authors.initials: S
authors.lastname: Krähenbühl
authors.forename: Michael
authors.initials: M
authors.lastname: Mayr
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D004164:Diphosphonates / Q000494:pharmacology*; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D007668:Kidney / Q000473:pathology; D008297:Male; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D009404:Nephrotic Syndrome / Q000188:drug therapy / Q000209:etiology*; D013997:Time Factors; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid